JPWO2021181234A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021181234A5 JPWO2021181234A5 JP2022554330A JP2022554330A JPWO2021181234A5 JP WO2021181234 A5 JPWO2021181234 A5 JP WO2021181234A5 JP 2022554330 A JP2022554330 A JP 2022554330A JP 2022554330 A JP2022554330 A JP 2022554330A JP WO2021181234 A5 JPWO2021181234 A5 JP WO2021181234A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ppm
- cis
- site
- biofilm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 65
- 239000003242 anti bacterial agent Substances 0.000 claims 12
- 229940088710 antibiotic agent Drugs 0.000 claims 12
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims 8
- 241000894006 Bacteria Species 0.000 claims 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- WXBXVVIUZANZAU-HJWRWDBZSA-N cis-2-decenoic acid Chemical compound CCCCCCC\C=C/C(O)=O WXBXVVIUZANZAU-HJWRWDBZSA-N 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 4
- 229930186147 Cephalosporin Natural products 0.000 claims 3
- 229940126574 aminoglycoside antibiotic Drugs 0.000 claims 3
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims 3
- 230000000844 anti-bacterial effect Effects 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 229940124587 cephalosporin Drugs 0.000 claims 3
- 150000001780 cephalosporins Chemical class 0.000 claims 3
- 230000001332 colony forming effect Effects 0.000 claims 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 3
- 229930195729 fatty acid Natural products 0.000 claims 3
- 239000000194 fatty acid Substances 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000005642 Oleic acid Substances 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000002745 absorbent Effects 0.000 claims 2
- 239000002250 absorbent Substances 0.000 claims 2
- SNTXNGAQYNSTHI-LUAWRHEFSA-N cis-11-Methyl-2-dodecenoic acid Chemical compound CC(C)CCCCCCC\C=C/C(O)=O SNTXNGAQYNSTHI-LUAWRHEFSA-N 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 1
- 229930182566 Gentamicin Natural products 0.000 claims 1
- 108010059993 Vancomycin Proteins 0.000 claims 1
- 206010048038 Wound infection Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000032770 biofilm formation Effects 0.000 claims 1
- 229960001139 cefazolin Drugs 0.000 claims 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960002518 gentamicin Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 229960003165 vancomycin Drugs 0.000 claims 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 1
Claims (32)
溶媒中に可溶化され、約１００ｐｐｍ～約１０００ｐｐｍの範囲の濃度を有する、シス一価不飽和脂肪酸を含み、
前記組成物は、前記組成物が細菌から形成されたバイオフィルムに適用されるとき、前記細菌のコロニー形成単位（ＣＦＵ）の、少なくとも１．０の対数減少値として測定される殺菌効果を発揮するように構成されており、
前記シス一価不飽和脂肪酸が、シス－２－アルケン酸であり、
前記組成物が、抗生物質剤を更に含み、
前記組成物における前記抗生物質剤の濃度が、約５ｐｐｍ～約１５ｐｐｍの範囲内であり、
前記抗生物質剤が、アミノグリコシド抗生物質、セファロスポリン抗生物質、もしくはグリコペプチド抗生物質、またはそれらの組み合わせである、組成物。 A composition for treating a bacterial biofilm-mediated infection, the composition comprising:
cis monounsaturated fatty acids solubilized in a solvent and having a concentration ranging from about 100 ppm to about 1000 ppm;
The composition exhibits a bactericidal effect measured as a log reduction of colony forming units (CFU) of the bacteria of at least 1.0 when the composition is applied to a biofilm formed from the bacteria. It is configured as follows.
the cis-monounsaturated fatty acid is a cis-2-alkenoic acid,
the composition further comprises an antibiotic agent;
the concentration of the antibiotic agent in the composition is within the range of about 5 ppm to about 15 ppm;
The composition , wherein the antibiotic agent is an aminoglycoside antibiotic, a cephalosporin antibiotic, or a glycopeptide antibiotic, or a combination thereof .
溶媒中に可溶化され、約１００ｐｐｍ～約１０００ｐｐｍの範囲の濃度を有する、シス一価不飽和脂肪酸を含み、
前記組成物は、前記組成物が細菌から形成されたバイオフィルムに適用されるとき、前記細菌のコロニー形成単位（ＣＦＵ）の、少なくとも１．０の対数減少値として測定される殺菌効果を発揮するように構成されており、
前記シス一価不飽和脂肪酸が、シス－２－アルケン酸であり、
前記組成物が、抗生物質剤を更に含み、
前記組成物における前記抗生物質剤の濃度が、約５ｐｐｍ～約１５ｐｐｍの範囲内であり、
前記抗生物質剤が、アミノグリコシド抗生物質、セファロスポリン抗生物質、もしくはグリコペプチド抗生物質、またはそれらの組み合わせであり、前記方法が、
前記バイオフィルムを含む部位を識別することと、
前記組成物を、前記部位に適用することと、
を含む、組成物。 A composition for use in a method of treating a site of biofilm -derived infection, the composition comprising:
cis monounsaturated fatty acids solubilized in a solvent and having a concentration ranging from about 100 ppm to about 1000 ppm;
The composition exhibits a bactericidal effect measured as a log reduction of colony forming units (CFU) of the bacteria of at least 1.0 when the composition is applied to a biofilm formed from the bacteria. It is configured as follows.
the cis-monounsaturated fatty acid is a cis-2-alkenoic acid,
the composition further comprises an antibiotic agent;
the concentration of the antibiotic agent in the composition is within the range of about 5 ppm to about 15 ppm;
the antibiotic agent is an aminoglycoside antibiotic, a cephalosporin antibiotic, or a glycopeptide antibiotic, or a combination thereof, and the method comprises:
identifying a site containing the biofilm;
applying the composition to the site;
A composition comprising.
溶媒中に可溶化され、約１００ｐｐｍ～約１０００ｐｐｍの範囲の濃度を有する、シス一価不飽和脂肪酸を含み、
前記組成物は、前記組成物が細菌から形成されたバイオフィルムに適用されるとき、前記細菌のコロニー形成単位（ＣＦＵ）の、少なくとも１．０の対数減少値として測定される殺菌効果を発揮するように構成されており、
前記シス一価不飽和脂肪酸が、シス－２－アルケン酸であり、
前記組成物が、抗生物質剤を更に含み、
前記組成物における前記抗生物質剤の濃度が、約５ｐｐｍ～約１５ｐｐｍの範囲内であり、
前記抗生物質剤が、アミノグリコシド抗生物質、セファロスポリン抗生物質、もしくはグリコペプチド抗生物質、またはそれらの組み合わせであり、前記方法が、
バイオフィルム由来感染症にかかりやすい創傷部位または外科手術部位を識別することと、
前記組成物を、前記部位に適用することと、
を含む、組成物。 A composition for use in a method of inhibiting biofilm formation at a wound or surgical site, the composition comprising:
cis monounsaturated fatty acids solubilized in a solvent and having a concentration ranging from about 100 ppm to about 1000 ppm;
The composition exhibits a bactericidal effect measured as a log reduction of colony forming units (CFU) of the bacteria of at least 1.0 when the composition is applied to a biofilm formed from the bacteria. It is configured as follows.
the cis-monounsaturated fatty acid is a cis-2-alkenoic acid,
the composition further comprises an antibiotic agent;
the concentration of the antibiotic agent in the composition is within the range of about 5 ppm to about 15 ppm;
the antibiotic agent is an aminoglycoside antibiotic, a cephalosporin antibiotic, or a glycopeptide antibiotic, or a combination thereof, and the method comprises:
identifying wound or surgical sites susceptible to biofilm-derived infections;
applying the composition to the site;
A composition comprising.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062986997P | 2020-03-09 | 2020-03-09 | |
| US62/986,997 | 2020-03-09 | ||
| PCT/IB2021/051876 WO2021181234A1 (en) | 2020-03-09 | 2021-03-05 | Bactericidal debridement compositions for surgical site infections and chronic wound healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519168A JP2023519168A (en) | 2023-05-10 |
| JPWO2021181234A5 true JPWO2021181234A5 (en) | 2024-03-07 |
Family
ID=74870859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554330A Pending JP2023519168A (en) | 2020-03-09 | 2021-03-05 | Bactericidal debridement composition for surgical site infections and chronic wound healing |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11826333B2 (en) |
| EP (1) | EP4117651A1 (en) |
| JP (1) | JP2023519168A (en) |
| CN (1) | CN115279362A (en) |
| AU (1) | AU2021233221A1 (en) |
| BR (1) | BR112022017985A2 (en) |
| CA (1) | CA3174713A1 (en) |
| WO (1) | WO2021181234A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114306307A (en) * | 2022-01-20 | 2022-04-12 | 西安英创生物技术有限公司 | Application of DSF in preparing anti-inflammatory drugs or anti-oxidation drugs and drugs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2513918B2 (en) | 1989-08-17 | 1996-07-10 | 日本ペイント株式会社 | Water dispersion type coating composition |
| JPH0830171B2 (en) | 1989-08-17 | 1996-03-27 | 日本ペイント株式会社 | Solvent type coating composition |
| US5556913A (en) | 1989-12-04 | 1996-09-17 | Nippon Paint Co., Ltd. | Cationic electrocoating composition |
| DE112008001301T5 (en) | 2007-05-14 | 2010-04-29 | Reserach Foundation Of State University Of New York | Induction of a physiological dispersion response in bacterial cells in a biofilm |
| WO2010107794A2 (en) | 2009-03-16 | 2010-09-23 | University Of Memphis Research Foundation | Compositions and methods for delivering an agent to a wound |
| WO2014142915A1 (en) | 2013-03-14 | 2014-09-18 | University Of Memphis Research Foundation | Methods for producing a biodegradable chitosan composition and uses thereof |
| JP6538087B2 (en) | 2014-05-30 | 2019-07-03 | ザ・セカント・グループ・エルエルシー | Waterborne manufacture of polymeric materials |
| US9801909B2 (en) | 2015-04-06 | 2017-10-31 | The Penn State Research Foundation | Compositions and methods for combating bacterial infections by killing persister cells with mitomycin C |
| US11541105B2 (en) * | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
-
2021
- 2021-03-05 JP JP2022554330A patent/JP2023519168A/en active Pending
- 2021-03-05 EP EP21711374.5A patent/EP4117651A1/en active Pending
- 2021-03-05 CA CA3174713A patent/CA3174713A1/en active Pending
- 2021-03-05 WO PCT/IB2021/051876 patent/WO2021181234A1/en unknown
- 2021-03-05 AU AU2021233221A patent/AU2021233221A1/en active Pending
- 2021-03-05 CN CN202180020114.0A patent/CN115279362A/en active Pending
- 2021-03-05 US US17/193,196 patent/US11826333B2/en active Active
- 2021-03-05 BR BR112022017985A patent/BR112022017985A2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11826332B2 (en) | Antimicrobial compositions and uses thereof | |
| EP1998615B1 (en) | Antimicrobial composition | |
| US7314857B2 (en) | Synergistic antimicrobial compositions and methods of inhibiting biofilm formation | |
| DE60116052T2 (en) | POLYMER MIXTURES AS BIOABBAUBARE MATRICES FOR THE PRODUCTION OF BIOCOMPOSITES | |
| AU2002320366B8 (en) | Method for treating medical devices using glycerol and an antimicrobial agent | |
| US11191274B2 (en) | Biofilm penetrating compositions and methods | |
| JPH11504241A (en) | Catheter and medical implant injected with antimicrobial agent and method for injecting the same | |
| US20220347138A1 (en) | Wound care product | |
| Jang et al. | Effect of vancomycin-coated tympanostomy tubes on methicillin-resistant Staphylococcus aureus biofilm formation: in vitro study | |
| WO2005099655A2 (en) | Antimicrobial cleansing compositions and methods of use | |
| US8426044B2 (en) | Method for imparting antimicrobial activity to a medical device | |
| EP2854888B1 (en) | Lipoic acid compositions useful as antimicrobial agents | |
| JPWO2021181234A5 (en) | ||
| CN115279362A (en) | Bactericidal debridement composition for surgical site infection and chronic wound healing | |
| EP2892342B1 (en) | An antibiofilm and methods for making and using the same | |
| US20150328377A1 (en) | Composition of d-alpha hydroxy acids and antimicrobials | |
| JP2018520838A (en) | Implantable orthopedic device with antimicrobial coating | |
| CN110636839A (en) | Liposomes for inhibiting biofilm formation | |
| KR20240003296A (en) | Long-acting antibiotic for treatment of diabetic foot and surgical site infection | |
| Krzemiński et al. | The use of octenidine dihydrochloride in the treatment of musculoskeletal infections | |
| Simionescu et al. | Prevention of Infection in Prosthetic Devices |